No profile data available.
Arcus Biosciences, Inc. (RCUS) is a healthcare company in the additional cancer treatment drugs industry, based in Hayward, United States, with about 601 full-time employees.
It reported revenue of $258.00 million for fiscal year 2024, up 120.5% from fiscal year 2023, and net income of -$283.00 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $26.00 million, down 45.8% from a year before. Its market capitalization was $3.11 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.
Arcus Biosciences reported $258.00 million in revenue for fiscal year 2024, up 120.5% from $117.00 million in fiscal year 2023. In Q3 2025 revenue was $26.00 million.
$3.11 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Cogent Biosciences, Inc. (COGT), Relay Therapeutics, Inc. (RLAY), Ideaya Biosciences, Inc. (IDYA), Enliven Therapeutics, Inc. (ELVN).